Calcipotriene vs Calcipotriene and Betamethasone Dipropionate — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Vitamin D Analog

Calcipotriene

Brand: Calcitrene

First FDA approval: 1996-10-01

Vitamin D Analog

Calcipotriene and Betamethasone Dipropionate

Brand: ENSTILAR

First FDA approval: 2008-06-01

Lowest NADACAcquisition cost floor across all NDCs

$1.10Per unit

$0.886Per unit

Average NADACAcross all dosage forms and strengths

$1.65Up to $2.69

$6.54Up to $21.80

Generic manufacturersActive ANDA holders — FDA Orange Book

55 total ANDAs filed

33 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$35.6MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

226K131K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$157Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

265Substantial friction

60Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

1Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes3 manufacturers